Egis Pharmaceuticals made a net profit of HUF 18,531 mil under revenues of HUF 132,825 mil in 2012, up 36.4% and 3.01%, respectively, when compared to the last year. This translates into a net margin of 14.0%.
Historically, the firm’s net profit reached an all time high of HUF 18,531 mil in 2012 and an all time low of HUF 5,540 mil in 2003. Since 2007, the firm's net profit has increased 143% or 19.4% a year on average.
On the operating level, EBITDA reached HUF 30,536 mil, up 19.2% when compared to the previous year. Over the last five years, company's EBITDA has grown 15.9% a year on average.
As far as Egis Pharmaceuticals's peers are concerned, Gedeon Richter posted net and EBITDA margin of 15.1% and 23.1%, respectively in 2012, Krka generated margins of 14.0% and 24.5% and Sanofi-Aventis Czech Republic's profit margin reached 0.626% on the net and 1.12% on the EBITDA level in 2012.